GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Annie W. Lin, PhD, RD
- Número de telefone: (612) 356 2001
- E-mail: awlin@umn.edu
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion
Survivors of GI cancer are eligible if they are:
- ≥18 years old
- reside in or have received cancer care in Minnesota
- own a smartphone • consent to install the GutCheck app and discontinue diet tracking in other lifestyle apps (e.g., MyFitness, Fitbit, Noom).
- are English-speaking
- have received a GI cancer diagnosis (e.g., esophageal, gastric, colorectal, liver, pancreatic, etc)
- At least 2 months post-cancer treatment
Inclusion criteria for oncology specialists (oncologists, advanced practice providers, nurses, dietitians, and patient navigators) include:
- Have interacted with at least 1 cancer patient or survivor in the past month.
- Have experience working with electronic health records (EHR).
Exclusion
- Currently pregnant (Patient Study ONLY)
- Pregnancy status may be self-reported by the participant.
- Individuals who are postmenopausal, surgically sterile, or otherwise unable to become pregnant are not subject to this exclusion.
- Active cancer or receiving treatment for another cancer.
- Currently taking or has taken antibiotics in the last 3 months.
- Diagnosis of inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), and/or celiac disease.
- Involuntary weight loss of 10% or more of usual body weight within 6 months, or involuntary loss of 5% or more of usual body weight in 1 month.
Oncology specialists' exclusion criteria include:
- Unable to participate in an interview
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Personalization Level - No
The "no personalization" group will receive generic push messages based on United States Department of Agriculture and Centers for Disease Control and Prevention recommendations.
Within their personalization level, participants will be automatically randomized daily to varying message frequency (one vs. three times per day) and timing (preferred times vs. established times).
After each message, all participants will be asked to evaluate whether the message was useful using a 3-point Likert-type visual scale in the app.
|
Participants who were selected to collect their stool samples will be mailed their second kit before the last week (week 8) of intervention.
Participants will collect their stool sample during week 8 and mail them to be processed prior to the Exit Interview Visit.
Participants will be asked to log their food and beverages, stress, and gastrointestinal symptoms daily.
They will also track physical activity.
|
|
Comparador Ativo: Personalization Level - Low
The "low personalization" group will receive similar messages, with occasional use of their names and references to GI cancer.
Within their personalization level, participants will be automatically randomized daily to varying message frequency (one vs. three times per day) and timing (preferred times vs. established times).
After each message, all participants will be asked to evaluate whether the message was useful using a 3-point Likert-type visual scale in the app.
|
Participants who were selected to collect their stool samples will be mailed their second kit before the last week (week 8) of intervention.
Participants will collect their stool sample during week 8 and mail them to be processed prior to the Exit Interview Visit.
Participants will be asked to log their food and beverages, stress, and gastrointestinal symptoms daily.
They will also track physical activity.
|
|
Comparador Ativo: Personalization Level - High
The "high personalization" group messages will be further tailored to age and gender to provide social comparisons.
This group will receive food-related GI messages based on their responses from the personalization quiz during Week 1. Messages will emphasize affordable, commonly available foods to increase likelihood of accessibility.
Within their personalization level, participants will be automatically randomized daily to varying message frequency (one vs. three times per day) and timing (preferred times vs. established times).
After each message, all participants will be asked to evaluate whether the message was useful using a 3-point Likert-type visual scale in the app.
|
Participants who were selected to collect their stool samples will be mailed their second kit before the last week (week 8) of intervention.
Participants will collect their stool sample during week 8 and mail them to be processed prior to the Exit Interview Visit.
Participants will be asked to log their food and beverages, stress, and gastrointestinal symptoms daily.
They will also track physical activity.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence of Diet Tracking
Prazo: 1 year
|
Average count of days where the participant tracked at least two episodes a day.
|
1 year
|
|
Adherence of Gastrointestinal (GI) Symptom and Stress Level Tracking
Prazo: 1 year
|
Average count of days of GI symptom and stress tracking combination (i.e., once a day for two weeks for both).
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2025LS135
- MNCCTN038 (Outro identificador: Minnesota Clinical Trials Network (MNCCTN))
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .